As of July 1st, 2023, Australia has made MDMA- and Psilocybin-Assisted Therapies available to those in need. MDMA-AT is now available for PTSD, and Psilocybin-AT is available for treatment-resistant depression.
Interestingly, the Australian government brought in these legislative changes despite the lack of support from the Australian Psychiatric as well as Medical Associations, both of which expressed concern that the safety and efficacy of these therapies have not yet been fully examined (I assume meaning the US FDA has not yet completed the process of approving these therapies for medical use). However, the Australian government has apparently been swamped with desperate requests from the public to make these therapies available, and they responded in kind.
As a result, at this time, Australia is the country where MDMA- and Psylocibin-Assisted Therapies are easier to access than anywhere else in the world.
However, easier does not mean these therapies are easy to access. Treating psychiatrists are still required to submit individual applications outlining specific treatment plans, the credentials of the treatment team, and so on, which is similar to what is currently required for the Canadian Special Access Program or the US Extended Access Program for these therapies. The main difference (if I understand it correctly) is that Canada and the US require that PTSD or Depression be life-threatening to approve Special or Extended Access applications, which is a pretty high threshold that makes access to these treatments in Canada and US very difficult at this time.
The best current estimate for when there will be widespread availability of MDMA- and Psilocybin- Assisted Therapies in Canada and the US is sometime in 2024. However, many regulatory issues are still unclear. And of course, no one yet knows how these expensive therapies will be paid for, making the issue of equitable access one of the most urgent issues surrounding these new therapies.
